Alto Neuroscience (NYSE: ANRO) recently received a number of ratings updates from brokerages and research firms:8/1/2026 – Alto Neuroscience was downgraded by Wall Street Zen from “sell” to “strong sell”. 7/29/2026 – Alto Neuroscience had its “sell (d-)” rating reaffirmed by Weiss Ratings. 7/18/2026 – Alto Neuroscience was upgraded by Wall Street Zen from “strong sell” to “sell”. Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. Featured StoriesReceive News & Ratings for Alto Neuroscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.